- Home
- ALLT vs ALMS Comparison
ALLT vs ALMS Comparison
Compare ALLT & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- ALMS
- Stock Information
- Founded
- ALLT 1996
- ALMS 2021
- Country
- ALLT Israel
- ALMS United States
- Employees
- ALLT 495
- ALMS N/A
- Industry
- ALLT Telecommunications Equipment
- ALMS
- Sector
- ALLT Telecommunications
- ALMS
- Exchange
- ALLT Nasdaq
- ALMS NYSE
- Market Cap
- ALLT 342.5M
- ALMS 402.6M
- IPO Year
- ALLT 2006
- ALMS 2024
- Fundamental
- Price
- ALLT $9.61
- ALMS $3.01
- Analyst Decision
- ALLT Buy
- ALMS Strong Buy
- Analyst Count
- ALLT 1
- ALMS 7
- Target Price
- ALLT $13.00
- ALMS $24.50
- AVG Volume (30 Days)
- ALLT 383.6K
- ALMS 1.0M
- Earning Date
- ALLT 05-12-2025
- ALMS 08-12-2025
- Dividend Yield
- ALLT N/A
- ALMS N/A
- EPS Growth
- ALLT N/A
- ALMS N/A
- EPS
- ALLT N/A
- ALMS N/A
- Revenue
- ALLT $93,455,000.00
- ALMS $17,389,000.00
- Revenue This Year
- ALLT $9.08
- ALMS N/A
- Revenue Next Year
- ALLT $6.09
- ALMS N/A
- P/E Ratio
- ALLT N/A
- ALMS N/A
- Revenue Growth
- ALLT N/A
- ALMS N/A
- 52 Week Low
- ALLT $2.14
- ALMS $2.77
- 52 Week High
- ALLT $9.92
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- ALLT 71.62
- ALMS N/A
- Support Level
- ALLT $7.86
- ALMS N/A
- Resistance Level
- ALLT $9.08
- ALMS N/A
- Average True Range (ATR)
- ALLT 0.43
- ALMS 0.00
- MACD
- ALLT 0.01
- ALMS 0.00
- Stochastic Oscillator
- ALLT 84.89
- ALMS 0.00
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.